A Review of Omadacycline for Potential Utility in the Military Health System for the Treatment of Wound Infections.

ABSTRACT:

Introduction

Combat-related wound infections complicate the recovery of wounded military personnel, contributing to overall morbidity and mortality. Wound infections in combat settings present unique challenges because of the size and depth of the wounds, the need to administer emergency care in the field, and the need for subsequent treatment in military facilities. Given the increase in multidrug-resistant pathogens, a novel, broad-spectrum antibiotic is desired across this continuum of care when the standard of care fails. Omadacycline was FDA-approved in 2018 for treatment of adults with acute bacterial skin and skin structure infections (ABSSSI), as well as community-acquired bacterial pneumonia (CABP). It is a broad-spectrum antibiotic with activity against gram-positive, gra

SUBMITTER: Zurawski DV 

PROVIDER: S-EPMC11110612 | biostudies-literature | 2024 May

REPOSITORIES: biostudies-literature